Obsidian Therapeutics is thrilled to announce a major milestone in our journey to redefine the landscape of cell and gene therapy. We have successfully raised $325,000,000 in funding—a robust financial boost that underscores the confidence of blue chip investors, leading advisors, and our industry partners in our vision and technological advancements. At the core of our innovation is the proprietary cytoDriveTM technology, a powerful platform that enables the precise control of protein expression in cell and gene therapy products, thereby enhancing therapeutic efficacy. This capital infusion will accelerate the development of our lead program, cytoTIL15, which is engineered to boost the effectiveness of Tumor Infiltrating Lymphocytes (TILs) for a broader patient population facing intractable diseases.
Our mission to deliver transformative outcomes for patients has always been driven by a deep commitment to innovation, collaboration, and inclusion. With our state-of-the-art facility in Cambridge and our new laboratory in Bedford, we continue to foster an environment where our diverse and talented team can thrive. At Obsidian Therapeutics, we believe in investing not only in groundbreaking therapies but also in our people by offering competitive salaries, comprehensive benefits, and opportunities for employee ownership through stock options. This funding will empower our experienced team to advance our cutting-edge programs and expand our collaborative efforts with top-tier professionals in the field, ensuring that we remain at the forefront of medical innovation. As we commemorate this funding achievement, we look forward to transforming ambitious scientific breakthroughs into tangible, life-changing treatments for patients worldwide.
